Irritable Bowel Syndrome (IBS) Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | 4D Pharma, OrphoMed, RedHill Biopharma, Takeda, CinRx Pharma, Rottapharm, Metacrine, Novome, Renexxion, Serentrix

The Irritable Bowel Syndrome Market size in the 7MM was approximately USD 1,800 million in 2022, and it is projected to increase during the forecast period. As per DelveInsight, the Irritable Bowel Syndrome Market is anticipated to evolve immensely in the coming years owing to the rise in the geriatric population, the increase in the prevalence of gastrointestinal diseases and disorders, unhealthy diets, and the expected commercial success of upcoming therapies in the 7MM.

Key players such as 4D Pharma (blautix), Cosmo Pharmaceuticals (rifamycin SV-MMX), RedHill Biopharma (RHB-102), Seed Health (DS-01), NGM Pharmaceuticals (aldafermin), and several others are evaluating their lead candidates in different stages of clinical development to improve the Irritable Bowel Syndrome treatment outlook.

DelveInsight's "Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Irritable Bowel Syndrome Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Irritable Bowel Syndrome therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Irritable Bowel Syndrome treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Irritable Bowel Syndrome (IBS): An Overview
Irritable bowel syndrome is a chronic functional bowel disease characterized by symptoms of abdominal pain and/or discomfort associated with altered bowel habits in the absence of a structural or organic cause. Based on bowel patterns at a particular point in time, the disorder may be categorized into four groups: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), mixed (IBS-M), and un-subtyped.

The precise cause of irritable bowel syndrome remains unknown. However, several factors have been implicated in the pathophysiology of irritable bowel syndrome symptoms, including genetic disposition, diet, intestinal microbiota, and low-grade mucosal inflammation. No specific biomarker related to irritable bowel syndrome has been found. Multiple risk factors have been strongly associated with irritable bowel syndrome development, including female sex, young age, tobacco smoking, and mental health disorders, mainly stress and anxiety.

Irritable Bowel Syndrome (IBS) Market Key Facts
• The market size in the 7MM will increase due to recent efforts to increase patient and clinician relationships and their awareness of Irritable Bowel Syndrome, with various awareness campaigns, are expected to increase early diagnosis and treatment of Irritable Bowel Syndrome.
• Among EU4 countries, Germany accounted for the maximum market size in 2022.
• By 2032, among all the emerging therapies, the highest revenue is expected to be generated by blautix, followed by RHB-102, and aldafermin in the 7MM.
• The total prevalent cases of Irritable Bowel Syndrome in the United States were around 14,410,000 cases in 2022.
• The US contributed to the largest prevalent population of Irritable Bowel Syndrome, acquiring ~46% of the 7MM in 2022. Whereas, Japan accounted for around 12% and Germany accounted for around 11% of the total population share, respectively, in 2022.
• Among EU4 countries, Germany accounted for the largest number of Irritable Bowel Syndrome cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, there were around 2,522,000, 2,234,000, 2,053,000, and 396,000 in diarrhea-predominant, mixed stool pattern, constipation-predominant, and unspecified irritable bowel syndrome, respectively in the United States in 2022. These cases are projected to increase during the forecasted period.
• In the 7MM, approximately 33% of the patient share is attributed to males, whereas only 67% of females suffer from Irritable Bowel Syndrome.
• The diagnosis and treatment rate of Irritable Bowel Syndrome is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of Irritable Bowel Syndrome, thus leading to an increase in awareness among patients and clinicians.

Discover How Irritable Bowel Syndrome Market Will Grow by 2032:
https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Irritable Bowel Syndrome (IBS) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Irritable Bowel Syndrome therapies in the market. It also provides a detailed assessment of the Irritable Bowel Syndrome market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Irritable Bowel Syndrome drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Irritable Bowel Syndrome (IBS) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Irritable Bowel Syndrome patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Irritable Bowel Syndrome Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Severity-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Total Treated Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Gender-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Total Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Subtype-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]
• Age-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM [2019-2032]

Get Key Insights Into the Evolving Irritable Bowel Syndrome Epidemiology Trends:
https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Irritable Bowel Syndrome (IBS) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Irritable Bowel Syndrome market or expected to be launched during the study period. The analysis covers the market share by Irritable Bowel Syndrome drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Irritable Bowel Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Irritable Bowel Syndrome (IBS) Therapeutics Assessment
Treatment of irritable bowel syndrome consists of stress relief, change in diet, proper medicines, and counseling. Medications for treating irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used to treat irritable bowel syndrome, including dicyclomine, peppermint oil, and hyoscyamine.

Several major pharma and biotech companies are developing therapies for Irritable bowel syndrome. Currently, OrphoMed is leading the therapeutics market with its Irritable bowel syndrome drug candidates in the most advanced stage of clinical development. The dynamics of the irritable bowel syndrome market are anticipated to change in the coming years owing to the emerging pipeline raising awareness of the diseases, and incremental healthcare spending worldwide.

Leading Companies in the Irritable Bowel Syndrome (IBS) Therapeutics Market Include
• Arena Pharmaceuticals
• 4D Pharma
• OrphoMed
• Boston Pharmaceuticals
• RedHill Biopharma Limited
• Takeda
• Cosmo Technologies
• CinRx Pharma
• Rottapharm
• Synthetic Biologics
• Biomica
• Metacrine
• MGC Pharma
• Napo Pharmaceuticals
• Novome Biotechnologies
• Renexxion
• Sentia Medical Sciences
• Serentrix LLC
• Vitality Biopharma
And Many Others

Emerging and Marketed Irritable Bowel Syndrome Therapies Covered in the Report Include
• ORP-101: OrphoMed
• Blautix: 4D Pharma
• Blautix (MRx1234): 4D pharma
• Rifamycin SV-MMX: Cosmo Pharmaceuticals
• VIBERZI/TRUBERZI (eluxadoline): Abbvie
• LINZESS/CONSTELLA (linaclotide): Ironwood Pharmaceuticals/ Abbvie/ Astellas Pharma
And Many More

Learn More About the Emerging Therapies & Key Companies in the Irritable Bowel Syndrome Therapeutics Market:
https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Irritable Bowel Syndrome Competitive Intelligence Analysis
4. Irritable Bowel Syndrome Market Overview at a Glance
5. Irritable Bowel Syndrome Background and Overview
6. Irritable Bowel Syndrome Patient Journey
7. Irritable Bowel Syndrome Epidemiology and Patient Population
8. Irritable Bowel Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Irritable Bowel Syndrome Unmet Needs
10. Key Endpoints of Irritable Bowel Syndrome Treatment
11. Irritable Bowel Syndrome Marketed Products
12. Irritable Bowel Syndrome Emerging Therapies
13. Irritable Bowel Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Irritable Bowel Syndrome Market Outlook (7 major markets)
16. Irritable Bowel Syndrome Access and Reimbursement Overview
17. KOL Views on the Irritable Bowel Syndrome Market.
18. Irritable Bowel Syndrome Market Drivers
19. Irritable Bowel Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market

Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market

Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.